资讯

pharmaphorum2 天
Update: FDA clears first generic of AZ's blockbuster Symbicort
Viatris (formerly Mylan) has become the first drugmaker to win full FDA approval for a generic version of AstraZeneca's top-selling respiratory drug Symbicort, although launch plans remain ...
pharmaphorum2 天
AstraZeneca breathes sigh of relief as court blocks US Symbicort generic
A US court has upheld AstraZeneca’s patents on its respiratory drug Symbicort, blocking cheaper competition for the ageing blockbuster.
MedPage Today on MSN4 天
Switch to Dry-Powder Inhaler Worsened COPD, Asthma Patient Outcomes
Shifting from a metered-dose inhaler to a dry-powder inhaler for chronic obstructive pulmonary disease (COPD) and asthma in ...
Zacks Investment Research on MSN1 天
TEVA Stock Up More than 20% in Three Months: Buy, Sell or Hold the Stock?
Teva Pharmaceutical Industries Limited’s TEVA shares have risen 21.6% in three months. Over the past few quarters, Teva has ...